MiNK Q2 net loss narrows to $2.7M; cash $9.3M; clinical programs advance

MiNK Therapeutics, Inc.

2024-Q2 EPS reported -$0.18

Net loss Q2 2024 $2.7M ($0.07/sh) vs $6.2M ($0.18/sh) Q2 2023; 6-month loss $6.5M vs $11.9M.
Cash $9.3M at Jun 30, up from $3.4M at Dec 31; cash used in ops $2.3M for Q2, reduced from $4.2M YoY.
Closed $5.8M PIPE at 25% premium to new investor; cash runway extended into 2025.
AgenT-797: Phase 2 gastric cancer advancing, early data at upcoming conference; Phase 1 GvHD activation planned; ARDS expanded access shows clinical benefit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.